Veradermics Sets Oct 19 Call to Unveil Phase 3 Hair-Loss Trial Results
MANE has more than doubled off its 52-week low of $32.
Summary
Veradermics will host an investor call Monday, October 19 at 8:00 am ET to review topline results from Part A of Study '304', the Phase 3 trial of oral extended-release minoxidil VDPHL01 in 536 men with mild-to-moderate pattern hair loss. The call timing means the data lands essentially now — this is the first pivotal readout for the lead program and the main near-term driver for a company with a roughly $4.5 billion market cap and no approved product. The trial's co-primary endpoints are change in target area hair count and patient-reported hair coverage improvement at Month 6; a clean hit supports the broader three-trial program (over 1,600 patients) aimed at the first FDA-approved oral non-hormonal treatment for pattern hair loss. Context worth weighing: this comes after a wave of insider selling in August, including a $80.4 million block at $107.25 and a CEO plan to sell $15 million, so a strong dataset would need to overcome a skeptical ownership backdrop.
At the time of this announcement, MANE was trading at $108.82 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $32.00 to $136.72. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.